Katie Ellias
Managing Director at T1D Fund
Katie Ellias
Managing Director at T1D Fund
Greater Boston
Overview
Work Experience
Managing Director
2018 - Current
The Fund is a venture philanthropy fund committed to accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through catalytic equity investments. While independently managed, the Fund is affiliated with JDRF, the leading global organization funding T1D research. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance cures and therapies into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund reinvests any realized gains into new investments to further its mission.
Board Member
2023
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Raised $186,320,000.00 from Marshall Wace, RA Capital Management, Commodore Capital, Sessa Capital, RTW Investments, JDRF T1D Fund, Biotechnology Value Fund and T. Denny Sanford.
Board Member
2020
Board Observer
2021
Seraxis is a privately owned biotechnology company.
Raised $40,400,000.00 from Maryland Stem Cell Research Fund (MSCRF).
Board Observer
2020
I2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies.
Raised $90,439,921.00 from Viva BioInnovator.
Board Member
2019
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.
Raised $47,460,000.00 from Hatteras Venture Partners, JDRF T1D Fund, Genesys Capital, Pappas Capital, NYBC Ventures and Sanofi Ventures.
Board Observer
2019
Biolinq develops a wearable biosensor platform that is capable of measuring blood level information.
Raised $254,251,237.00 from Niterra Ventures, Taisho Pharmaceutical Holdings, Features Capital, Aphelion Capital, Alpha Wave Ventures, Global Health Investment Corporation, Senvest Management, AXA Investment Managers, Pegasus Tech Ventures and RiverVest.
Board Observer
2018
Board Member
2021
Board Member
2019 - 2022
Capillary Biomedical is a medical device startup developing technologies for diabetes management.
Raised $4,485,000.00 from The Leona M. and Harry B. Helmsley Charitable Trust.